

PuriCore and ECT Sign Acquisition Agreement for ECT's Intellectual Property Assets

Patent portfolio focuses on complementary market sectors

MALVERN, PENNSYLVANIA, STAFFORD, UK, and ST. LOUIS, MISSOURI, 20 February 2008

— PuriCore (LSE: PURI), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, and Electro-Chemical Technologies Ltd. (“ECT”) announce the signing of an agreement for PuriCore to acquire ECT’s intellectual property portfolio. The acquisition includes nine issued U.S. patents related to electrolyzed water equipment and processes. Additionally, PuriCore has signed separate agreements to hire two senior ECT scientists who bring many years of collective experience in electrolyzed water technology. The deal will enable PuriCore to expand its operations in commercial and industrial water treatment.

Under terms of the agreement, PuriCore will pay a total of \$2.3 million at closing for the patent portfolio and non-compete agreements. ECT might receive future payments of up to \$6 million based on PuriCore net sales in certain segments, including water safety applications. PuriCore will also become responsible for the ongoing maintenance fees of the intellectual property, which are estimated to be approximately \$20,000 total for the life of the patents.

To facilitate the transaction, ECT has filed a petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the Eastern District of Missouri. ECT simultaneously has filed a motion with the Bankruptcy Court seeking approval of the transaction. The transaction is expected to complete in the second quarter of 2008, at which time the Company will make a further announcement.

Greg Bosch, Chief Executive of PuriCore, said:

“The acquisition of ECT’s assets enhances our existing intellectual property portfolio and will advance our research and development efforts. Moreover, it will expand our opportunities in commercial and industrial water treatment.”

Vadim G. Panichev, CEO and President of ECT, added

“PuriCore has proven its financial and technical capabilities in commercialising electrochemically activated solutions and we look forward to further development and commercialisation.”

About PuriCore

[PuriCore](#) (LSE: PURI) is a life sciences company focused on developing and commercializing proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of *M. tuberculosis*, *MRSA*, *E.coli*, Norovirus, Avian Influenza, HIV, Polio Virus, *Helicobacter pylori*, and *Legionella*. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.

To receive additional information on PuriCore, please visit PuriCore's website at www.puricore.com, which does not form part of this press release.

About ECT

To receive additional information on ECT (Pink Sheets: ELCH), please visit ECT's website at www.ectltd.net, which does not form part of this press release.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

Enquiries:

Ben Brewerton
Susan Quigley
[Financial Dynamics](#)
+44 (0) 207 831 3113

Greg Bosch, CEO
Keith A. Goldan, CFO
PuriCore
484-321-2700